Press Releases

 FOR IMMEDIATE RELEASE December 4, 2025 HEADLINE Esquire Highlights Breakthrough Hair-Loss Molecule PP-405 as Dermatologists Monitor Emerging Clinical Data SUMMARY A recent Esquire article spotlighting the investigational hair-loss therapy PP-405 has drawn widespread attention to the molecule’s early clinical results and novel mechanism of action. Dermatologists say the therapy represents part of a new wave of regenerative treatments aimed at reactivating dormant hair follicles rather than simply slowing hair loss. BACKGROUND: A NEW GENERATION OF HAIR-LOSS TREATMENTS Hair loss, particularly androgenetic alopecia, affects millions of people worldwide and remains one of the most common conditions seen in dermatology clinics. Existing therapies such as minoxidil and finasteride can slow progression or modestly stimulate regrowth but often fail to fully restore hair density for many patients. In recent years, advances in molecular biology and regenerative medicine have led to a surg...

FOR IMMEDIATE RELEASE December 4, 2025 HEADLINE New Phase III Data for Breezula® (Clascoterone) Shows Strong Hair-Count Gains and Robust Safety in Androgenetic Alopecia Trials SUMMARY Topical androgen receptor inhibitor Breezula® (clascoterone 5% solution) has met its co-primary endpoints in two Phase III trials, showing substantial improvements in scalp hair count over vehicle — raising hopes for a new non-systemic therapy for pattern hair loss. New York hair-loss specialist Dr. Dennis Porto comments on the promising data and what it could mean for patients. BACKGROUND: ANDROGENETIC ALOPECIA AND LIMITATIONS OF CURRENT THERAPIES Androgenetic alopecia (pattern hair loss) affects millions of men and women, and current approved treatments—topical minoxidil and oral finasteride—often yield incomplete results or require long-term use with variable patient tolerance. Many patients seek safer, more effective, and non-systemic options to preserve hair without systemic side effects or adher...